The combination of CIMAvax-EGF with ICIs may provide a potential therapeutic option for advanced lung cancer in the future, to ensure better tumor control, in terms of the good safety and immunogenic profile of CIMAvax-EGF. This evidence concerns the gene EGF and lung cancer.